IGANIDIPINE, (-)-

Details

Stereochemistry	UNKNOWN
Molecular Formula	C28H38N4O6
Molecular Weight	526.6245
Optical Activity	( - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCC(C)(C)CN3CCN(CC=C)CC3

InChI

InChIKey=QBTSPDQKRVMTRU-UHFFFAOYSA-N

InChI=1S/C28H38N4O6/c1-7-11-30-12-14-31(15-13-30)17-28(4,5)18-38-27(34)24-20(3)29-19(2)23(26(33)37-6)25(24)21-9-8-10-22(16-21)32(35)36/h7-10,16,25,29H,1,11-15,17-18H2,2-6H3

HIDE SMILES / InChI

Description
Sources: http://www.chemdrug.com/article/8/3285/16420800.html

Iganidipin is a new dihydropiridynic derivative of calcium antagonist. It is the only currently available calcium antagonist in the form of ophthalmic solution. Its topical administration increases ipsilateral optic nerve head blood flow in rabbits and monkeys and inhibits the contraction of blood vessels induced by endothelin -1. Iganidipin is also used for treat Angina pectoris and Hypertension.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7575741	Blocker 555

Conditions

Condition	Modality	Highest Phase	Product
Glaucoma 57 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19902393	Primary	Basic research	Unknown Approved Use Unknown
Angina pectoris 110 Sources: http://www.chemdrug.com/article/8/3285/16420800.html	Primary	Phase II 1147	Unknown Approved Use Unknown
Hypertension 575 Sources: http://www.chemdrug.com/article/8/3285/16420800.html	Primary	Withdrawn	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY510597	https://www.001chemical.com/chem/119687-33-1
BLD Pharm	BD134328	http://www.bldpharm.com/products/119687-33-1.html
Chem Scene	CS-6635	http://www.chemscene.com/119687-33-1.html
CSNpharm	CSN21683	https://www.csnpharm.com/products/iganidipine.html
eNovation Chemicals	D677200	https://www.enovationchem.com/ProductDetails.asp?ProductID=D677200
MedChem Express	HY-101685	https://www.medchemexpress.com/Iganidipine.html
Molcore	MC510597	https://www.molcore.com/product/119687-33-1
MuseChem	M020797	https://www.musechem.com/product/M020797.html
Smolecule	S580511	https://www.smolecule.com/products/s580511
THE BioTek	bt-368216	https://www.thebiotek.com/product/others/bt-368216

PubMed

Title	Date	PubMed
Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia.	2006-02-03	16413513

Patents

Sample Use Guides

In Vivo Use Guide

for rabbit: (14)C-iganidipine solution (0.03%, 30 microL) was instilled into one eye

Route of Administration: Topical

In Vitro Use Guide

Iganidipine (0.01-1 microM) increased the retinal ganglion cells (RGC) viability

Name

Type

Language

3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 2,2-DIMETHYL-3-(4-(2-PROPENYL)-1-PIPERAZINYL)PROPYL METHYL ESTER, (-)-

Preferred Name

English

IGANIDIPINE, (-)-

Common Name

English

3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-(2,2-DIMETHYL-3-(4-(2-PROPEN-1-YL)-1-PIPERAZINYL)PROPYL) 5-METHYL ESTER, (-)-

Systematic Name

English

Code System Code Type Description

CAS

752171-43-0

Created by admin on Mon Mar 31 23:41:12 GMT 2025 , Edited by admin on Mon Mar 31 23:41:12 GMT 2025

PRIMARY

FDA UNII

RR46DCE78A

Created by admin on Mon Mar 31 23:41:12 GMT 2025 , Edited by admin on Mon Mar 31 23:41:12 GMT 2025

PRIMARY

SUBSTANCE RECORD


					RR46DCE78A

IGANIDIPINE, (-)-

Details

SMILES

InChI

DescriptionSources: http://www.chemdrug.com/article/8/3285/16420800.html

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.chemdrug.com/article/8/3285/16420800.html